Want to see KR:005690 full AI Analyst Report?
Top Page
Pharmicell Co., Ltd
(005690)
Select Model
Select Model
Rating:70Outperform
Price Target:
₩10,780.00
Action:N/A
Date:10/28/26
The score is primarily supported by strong current profitability and a healthy, low-leverage balance sheet. This is tempered by weak technicals (bearish momentum and price below key moving averages) and some concern around cash-flow and revenue-growth consistency, while valuation is reasonable but the dividend yield offers limited support.
Positive Factors
Strong Profitability
The sharp improvement in profitability gives Pharmicell greater capacity to fund research, clinical development, and commercial activity internally. High gross, operating, and net margins also provide a stronger cushion against moderate cost pressure and support more durable earnings quality over the coming quarters.
Negative Factors
Inconsistent Revenue Growth
The uneven revenue pattern suggests that Pharmicell’s commercial performance may be lumpy rather than steadily compounding. Even with recent TTM growth, inconsistent expansion can make planning and resource allocation more difficult and may limit confidence that current profitability will persist across future reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
The sharp improvement in profitability gives Pharmicell greater capacity to fund research, clinical development, and commercial activity internally. High gross, operating, and net margins also provide a stronger cushion against moderate cost pressure and support more durable earnings quality over the coming quarters.
Read all positive factors
Pharmicell Co., Ltd (005690) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩613.71B
Dividend Yield0.49%
Average Volume (3M)1.20M
Price to Earnings (P/E)13.1
Beta (1Y)0.63
Revenue Growth51.28%
EPS Growth124.70%
CountryKR
Employees186
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)775.86
Shares Outstanding60,004,013
10 Day Avg. Volume508,165
30 Day Avg. Volume1,196,764
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)7.04
Price to Sales (P/S)7.65
P/FCF Ratio25.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)987
Revenue Forecast (FY)₩160.00B
Pharmicell Co., Ltd Business Overview & Revenue Model
Company Description
Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: B...
Pharmicell Co., Ltd Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 135.94B | 114.06B | 64.85B | 56.23B | 60.18B | 51.81B |
| Gross Profit | 59.93B | 50.01B | 21.33B | 14.96B | 23.82B | 23.17B |
| EBITDA | 47.00B | 36.81B | 9.43B | 8.44B | 8.90B | 12.87B |
| Net Income | 46.57B | 40.33B | 6.33B | 3.58B | 8.26B | 9.45B |
Balance Sheet | ||||||
| Total Assets | 184.15B | 157.42B | 99.26B | 92.52B | 112.69B | 95.81B |
| Cash, Cash Equivalents and Short-Term Investments | 65.67B | 56.84B | 11.20B | 14.03B | 25.96B | 36.24B |
| Total Debt | 25.53B | 14.59B | 686.00M | 3.03B | 16.84B | 17.25B |
| Total Liabilities | 40.78B | 33.54B | 12.83B | 12.12B | 32.98B | 30.46B |
| Stockholders Equity | 143.37B | 123.88B | 86.44B | 80.40B | 76.66B | 63.87B |
Cash Flow | ||||||
| Free Cash Flow | 26.12B | 33.60B | -839.98M | 5.79B | -11.04B | -9.54B |
| Operating Cash Flow | 41.02B | 41.05B | 3.50B | 11.81B | 7.91B | -5.22B |
| Investing Cash Flow | -68.72B | -32.33B | -6.80B | 5.92B | -20.53B | -9.35B |
| Financing Cash Flow | 13.71B | 12.48B | -3.22B | -18.71B | -269.81M | 18.51B |
Pharmicell Co., Ltd Technical Analysis
Negative
―
Price Trends
11316.20
Negative
11669.50
Negative
13801.50
Negative
Market Momentum
-476.48
Positive
40.97
Neutral
18.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:005690, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 11323.00, equal to the 50-day MA of 11316.20, and equal to the 200-day MA of 13801.50, indicating a bearish trend. The MACD of -476.48 indicates Positive momentum. The RSI at 40.97 is Neutral, neither overbought nor oversold. The STOCH value of 18.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:005690.
Pharmicell Co., Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₩613.71B | 13.10 | ― | 0.49% | 51.28% | 124.70% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₩253.61B | -2.70 | ― | ― | 84.72% | -480.97% | |
43 Neutral | ₩291.21B | -16.97 | ― | ― | 116.74% | -482.50% | |
43 Neutral | ₩2.52T | -30.15 | ― | ― | 23.25% | -58.35% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:005690
Pharmicell Co., Ltd
10,230.00
-6,961.53
-40.49%
KR:011000
GeneOne Life Science, Inc.
2,670.00
-7,680.00
-74.20%
KR:052020
STCube, Inc.
6,720.00
-1,630.00
-19.52%
KR:199800
ToolGen Incorporated
29,800.00
-26,559.59
-47.13%
KR:302440
SK bioscience Co.,Ltd.
32,150.00
-18,750.00
-36.84%
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
4,220.00
-8,460.00
-66.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.